MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced four poster presentations at the 35th Annual Meeting of the Society for Immunotherapy of Cancer, bein
Full Story >>
Vote
+16